LINK Strengthens Board with Appointment of Marc Lemaître
News Feb 25, 2015
LINK has announced the appointment of Dr Marc Lemaître to its company board as a non-executive Director. Dr Lemaître brings to LINK his extensive experience in the nucleic acids field, supporting LINK’s strategic direction in developing both its established nucleic acid reagents business and its growing range of innovative reagents for oligo therapeutics and diagnostics.
Since obtaining a PhD in Biochemistry from the University of Liège, Dr Lemaître has been working in the field of nucleic acids for over 25 years, holding senior positions within various high profile CMOs, Pharma and Biotech companies. Notably, he oversaw the implementation of IVD oligo production at Eurogentec, SA during 13 years with the company. Based in the USA since 2006, Marc worked for Glen Research before being appointed in 2009 as CEO of Girindus America, a CMO with a focus on the cGMP manufacture of oligonucleotides for therapeutic applications. Whilst there he also acted as President of Girindus AG. Since negotiating the merger between Nitto-Denko Avecia and the US operations of Girindus in 2013, Marc has been working as an independent consultant.
Commenting on his appointment, Dr Lemaître said: “I was deeply honoured to be offered the opportunity to join LINK’s board. I’ve known LINK for quite some time as a customer and so already appreciate how much effort the team focuses on customer satisfaction and product quality. It’s therefore a great pleasure to now be involved with the strategic definition of LINK’s future business, and I look forward to helping secure and develop the company’s leading position in the nucleic acid chemistry landscape.”
Dr David Ricketts, CEO of LINK, added: “We are delighted to have Marc on board. His vast experience in our industry, particularly in the largest market of oligonucleotide reagents, will be invaluable as we continue to build our company’s presence in the nucleic acids arena. Together with the recent incorporation of our Scientific Advisory Board, this appointment underlines our ambition and focus to meet customers’ needs on a global scale.”
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018